The US company uses human embryonic stem (hES) cells for the generation of retinal pigment epithelium (RPE) thus developing a regenerative medicine for ophthalmology which is injected into the subretinal space for the treatment of atrophy type (dry type) age-related macular degeneration. US experiments are in clinical phase II.
Astellas news release, November 10, 2015
Astellas acquires US Ocata Therapeutics for 379 Million USD, specialist for eye diseases